K. Altundag Et Al. , "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer , vol.33, Illinois, United States Of America, 2015
Altundag, K. Et Al. 2015. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer , (Illinois, United States Of America).
Altundag, K., Babacan, T., Efe, O., Hasirci, A. S., Demirci, F., Buyukhatipoglu, H., ... Balakan, O.(2015). Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer. . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America
Altundag, Kadri Et Al. "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 2015
Altundag, Kadri Et Al. "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer , Illinois, United States Of America, 2015
Altundag, K. Et Al. (2015) . "Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Kadri Altundag Et Al. }, title={Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer}, city={Illinois}, country={United States Of America}, year={2015}}